Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study).

Safety and efficacy of N-acetylcysteine in hospitalized patients with HIV-associated tuberculosis: An open-label, randomized, phase II trial (RIPENACTB Study).

Despite the availability of effective antimicrobials, tuberculosis (TB) is still a serious health threat. Mortality is even higher in people living with HIV who are diagnosed with TB. New therapies are needed to shorten the time required to cure TB and decrease fatality rates in this population. N-a...

Full description

Bibliographic Details
Main Authors: Izabella Picinin Safe, Marcus Vinícius Guimarães Lacerda, Vitoria Silva Printes, Adriana Ferreira Praia Marins, Amanda Lia Rebelo Rabelo, Amanda Araújo Costa, Michel Araújo Tavares, Jaquelane Silva Jesus, Alexandra Brito Souza, Francisco Beraldi-Magalhães, Cynthia Pessoa Neves, Wuelton Marcelo Monteiro, Vanderson Souza Sampaio, Eduardo P Amaral, Renata Spener Gomes, Bruno B Andrade, Marcelo Cordeiro-Santos
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2020-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0235381

Internet

https://doi.org/10.1371/journal.pone.0235381

Similar Items